Send me real-time posts from this site at my email
Chris L

Three Biotech Picks for Summer 2019

With summer approaching, the selling pressure on drug and biotech stocks is due to end. What are the biotech picks for the coming warm season?

Nektar Therapeutics $NKTR has a $100 PT from BTIG. At EULAR 2019, the company highlighted its IL-2 target and how this pathway is involved in autoimmune disease. 

The repeat pick for the summer is Regeneron $REGN. The stock topped $430+ and is about to break below $300 - $305. Support is at $270-$290 where valuations are compelling. The Eylea competition is exaggerated. Regeneron is reporting stronger revenue despite planned price cuts.

Bluebird bio earned a 'hold' at pt $120 but I am not yet convinced the stock is a compelling hold at this time. Allergan $AGN is getting lots of negative selling, triggered by a small short float growth from 1% to 2%. Hardly a convincing bear call based on speculation alone.

Third biotech pick: Incyte $INCY earned a buy call from Cowen and Co. At a recent conference, it explained its genetic profiling model. On May 24, the FDA approved its drug for treating GvHD. The kinase inhibitor is already approved for treating myelofibrosis and polycythemia vera..

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue